Acute kidney injury in infective endocarditis: A retrospective analysis.

Acute kidney injury Aminoglycosides Endocardite infectieuse Endocarditis Insuffisance rénale aiguë Prosthetic valve Prothèse valvulaire Vancomycin Vancomycine

Journal

Medecine et maladies infectieuses
ISSN: 1769-6690
Titre abrégé: Med Mal Infect
Pays: France
ID NLM: 0311416

Informations de publication

Date de publication:
Oct 2019
Historique:
received: 12 01 2018
revised: 26 07 2018
accepted: 18 03 2019
pubmed: 9 4 2019
medline: 23 4 2020
entrez: 9 4 2019
Statut: ppublish

Résumé

Acute kidney injury (AKI) is associated with high case fatality in infective endocarditis (IE), but epidemiological data on the frequency of AKI during IE is scarce. We aimed to describe the frequency and risk factors for AKI during the course of IE using Kidney Disease: Improving Global Outcomes consensual criteria. Using the French hospital discharge database (French acronym PMSI), we retrospectively reviewed the charts of 112 patients presenting with a first episode of probable or definite IE between January 2010 and May 2015. Seventy-seven patients (68.8%) developed AKI. In univariate analysis, risk factors for AKI were cardiac surgery for IE (n=29, 37.7% vs. n=4, 1.4%, P<0.0005), cardiac failure (n=29, 36.7% vs. n=1, 2.9%, P<0.0005), diabetes mellitus (n=14, 18.2% vs. n=1, 0.9%, P=0.034), and prosthetic valve IEs (n=24, 31.2% vs. n=4, 11.4%). No differences were observed for gentamicin exposure (n=57, 64% vs. n=32, 86.5%, P=0.286). Prosthetic valve IE, cardiac failure, and vancomycin exposure were independently associated with AKI with respective odds ratio of 5.49 (95% CI 1.92-17.9), 4.37 (95% CI 4.37-465.7), and 1.084 (1.084-16.2). Mean length of hospital stay was significantly longer in patients presenting with AKI than in controls (respectively 52.4±22.1 days vs. 39.6±12.6, P<0.005). AKI is very frequent during IE, particularly in patients with prosthetic valve IE, cardiac failure, and those receiving vancomycin.

Sections du résumé

BACKGROUND BACKGROUND
Acute kidney injury (AKI) is associated with high case fatality in infective endocarditis (IE), but epidemiological data on the frequency of AKI during IE is scarce. We aimed to describe the frequency and risk factors for AKI during the course of IE using Kidney Disease: Improving Global Outcomes consensual criteria.
METHODS METHODS
Using the French hospital discharge database (French acronym PMSI), we retrospectively reviewed the charts of 112 patients presenting with a first episode of probable or definite IE between January 2010 and May 2015.
RESULTS RESULTS
Seventy-seven patients (68.8%) developed AKI. In univariate analysis, risk factors for AKI were cardiac surgery for IE (n=29, 37.7% vs. n=4, 1.4%, P<0.0005), cardiac failure (n=29, 36.7% vs. n=1, 2.9%, P<0.0005), diabetes mellitus (n=14, 18.2% vs. n=1, 0.9%, P=0.034), and prosthetic valve IEs (n=24, 31.2% vs. n=4, 11.4%). No differences were observed for gentamicin exposure (n=57, 64% vs. n=32, 86.5%, P=0.286). Prosthetic valve IE, cardiac failure, and vancomycin exposure were independently associated with AKI with respective odds ratio of 5.49 (95% CI 1.92-17.9), 4.37 (95% CI 4.37-465.7), and 1.084 (1.084-16.2). Mean length of hospital stay was significantly longer in patients presenting with AKI than in controls (respectively 52.4±22.1 days vs. 39.6±12.6, P<0.005).
CONCLUSION CONCLUSIONS
AKI is very frequent during IE, particularly in patients with prosthetic valve IE, cardiac failure, and those receiving vancomycin.

Identifiants

pubmed: 30955847
pii: S0399-077X(18)30036-2
doi: 10.1016/j.medmal.2019.03.015
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

527-533

Informations de copyright

Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Auteurs

A Gagneux-Brunon (A)

Department of Infectious Diseases, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France; EA 3064, GIMAP, Jean-Monnet University, University of Lyon, 42000 Saint-Etienne, France; CIC 1408 Inserm, 42055 Saint-Etienne, France. Electronic address: amandine.gagneux-bruno@chu-st-etienne.fr.

A Pouvaret (A)

Department of Infectious Diseases, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France.

N Maillard (N)

EA 3064, GIMAP, Jean-Monnet University, University of Lyon, 42000 Saint-Etienne, France; Department of Nephrology, Dialysis, Transplantation and Hypertension, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France.

P Berthelot (P)

Department of Infectious Diseases, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France; EA 3064, GIMAP, Jean-Monnet University, University of Lyon, 42000 Saint-Etienne, France; Laboratory of Microbiology and Hygiene, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France; Infection Control Unit, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France.

M F Lutz (MF)

Department of Infectious Diseases, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France; CIC 1408 Inserm, 42055 Saint-Etienne, France.

C Cazorla (C)

Department of Infectious Diseases, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France; CIC 1408 Inserm, 42055 Saint-Etienne, France.

C Tulane (C)

Department of Cardiology, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France.

J F Fuzellier (JF)

Department of Cardiac Surgery, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France.

P O Verhoeven (PO)

Department of Infectious Diseases, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France; EA 3064, GIMAP, Jean-Monnet University, University of Lyon, 42000 Saint-Etienne, France; Laboratory of Microbiology and Hygiene, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France.

A Frésard (A)

Department of Infectious Diseases, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France; CIC 1408 Inserm, 42055 Saint-Etienne, France.

X Duval (X)

Inserm 1425, Inserm U1137, Centre d'Investigation Clinique, Université Paris-Diderot, Hôpital Bichat, AP-HP, 75018 Paris, France.

F Lucht (F)

Department of Infectious Diseases, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France; EA 3064, GIMAP, Jean-Monnet University, University of Lyon, 42000 Saint-Etienne, France; CIC 1408 Inserm, 42055 Saint-Etienne, France.

E Botelho-Nevers (E)

Department of Infectious Diseases, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France; EA 3064, GIMAP, Jean-Monnet University, University of Lyon, 42000 Saint-Etienne, France; CIC 1408 Inserm, 42055 Saint-Etienne, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH